Lago Oliver Jesús, Arjona Medina Irene, Martín García-Almenta Ester, Martín Gil Jorge, Sanz Sánchez Mercedes, Pérez Díaz María Dolores, Alonso Poza Alfredo, Turégano Fuentes Fernando, Torres García Antonio
Hospital General Universitario Gregorio Marañón, Madrid, España.
Cir Esp. 2012 Dec;90(10):647-55. doi: 10.1016/j.ciresp.2012.05.007. Epub 2012 Jun 27.
A multicentre, prospective, randomised, controlled, and simple blind clinical trial was started in January 2007, with the aim of demonstrating the efficacy of fibrin-based biological adhesives in the prevention of anastomotic leaks in the high risk digestive tract.
A study on the prevention of anastomotic healing defects by applying biological adhesives along the suture line began in January 2007, and included the hospitals, Gregorio Marañón, Universitario de San Carlos, and Hospital del Sureste, in Madrid. The enrolled patients were randomised to one of 2 groups: the study group in which the adhesive was applied to the suture line, and a control group in which it was not applied. The primary outcome of the study was the presence or absence of leaks. The trial was approved by the corresponding Clinical Research Ethics Committees and the Spanish Medicines Agency (AEMPS) and registered www.clinicaltrials.gov (NCT01306851). The authors declared not to have any conflict of interests with the company, Baxter, which markets the product in Spain.
A total of 104 patients were recruited between January 2007 and November 2010, of whom 52 were randomised to the study group, and 52 to the control group. A total of 22 anastomotic leaks were recorded, of which 7 (13.4%) were in the study group, and 15 (28.8%) in the control group (P=.046). The leak risk index was 0.384, which means that there was a 61% reduction in leaks in the patients who had the fibrin-based biological adhesive applied. There were 3 (5.7%) further surgeries in the study group, compared to 12 (23%) in the control group (P=.12). On analysing the mortality, it was observed that 3 patients in the study group and 4 patients in the control group died (5.7% vs. 7.7%, P=.5). No other significant differences were found as regards the type of suture, surgical time, or pre-surgical history, except that the use of drainages appeared to be a protective factor of anastomotic leak (P=.041), although the use or not of a drainage was not a controlled factor, but at the discretion of each surgeon.
Our study demonstrates, significantly, that in the 104 patients in the study that fibrin based biological adhesives are capable of preventing anastomotic leaks in the high risk digestive tract, reducing the risk of leaks by 61% and a further surgeries. This is the first clinical trial that shows these significant results. If our results are maintained at the end of the study, it will show that anastomotic leaks can be prevented with the application of these adhesives, thus their application may be recommended in all the anastomosis of the high risk digestive tract.
2007年1月启动了一项多中心、前瞻性、随机、对照、单盲临床试验,旨在证明纤维蛋白基生物粘合剂在预防高风险消化道吻合口漏方面的疗效。
2007年1月开始一项关于沿缝线应用生物粘合剂预防吻合口愈合缺陷的研究,参与医院包括马德里的格雷戈里奥·马拉尼翁医院、圣卡洛斯大学医院和东南医院。纳入患者被随机分为两组:一组为研究组,在缝线上应用粘合剂;另一组为对照组,不应用粘合剂。研究的主要结局是有无吻合口漏。该试验获得了相应临床研究伦理委员会和西班牙药品管理局(AEMPS)的批准,并在www.clinicaltrials.gov(NCT01306851)上注册。作者声明与在西班牙销售该产品的百特公司不存在任何利益冲突。
2007年1月至2010年11月共招募了104例患者,其中52例被随机分配到研究组,52例被分配到对照组。共记录到22例吻合口漏,其中研究组7例(13.4%),对照组15例(28.8%)(P = 0.046)。漏出风险指数为0.384,这意味着应用纤维蛋白基生物粘合剂的患者漏出风险降低了61%。研究组有3例(5.7%)患者需要再次手术,而对照组有12例(23%)(P = 0.12)。分析死亡率发现,研究组3例患者死亡,对照组4例患者死亡(5.7%对7.7%,P = 0.5)。在缝线类型、手术时间或术前病史方面未发现其他显著差异,不过引流的使用似乎是吻合口漏的一个保护因素(P = 0.041),尽管引流的使用与否并非控制因素,而是由每位外科医生自行决定。
我们的研究显著表明,在本研究的104例患者中,纤维蛋白基生物粘合剂能够预防高风险消化道的吻合口漏,将漏出风险降低61%并减少再次手术的需求。这是首个显示出这些显著结果的临床试验。如果在研究结束时我们的结果依然成立,将表明应用这些粘合剂可预防吻合口漏,因此在所有高风险消化道吻合术中都可推荐应用。